Follow-up of adults with noncritical COVID-19 two months after symptom onset

By Claudia Carvalho-Schneider, E. Laurent, A. Lemaignen, Émilie Beaufils, C. Bourbao-Tournois, S. Laribi, T. Flament, N. Ferreira-Maldent, F. Bruyère, K. Stéfic and 3 more. Clinical Microbiology and Infection, 2020

683 citations recorded by the source corpus.

Objectives To describe the clinical evolution and predictors of symptom persistence during 2 months' follow-up in adults with noncritical coronavirus disease 2019 (COVID-19). Methods We performed descriptive clinical follow-up (day (D) 7, D30 and D60) of 150 patients with noncritical COVID-19 confirmed by real-time reverse transcriptase PCR at Tours University Hospital from 17 March to 3 June 2020, including demographic, clinical and laboratory data collected from the electronic medical records and by phone call. Persisting symptoms were defined by the presence at D30 or D60 of at least one of the following: weight loss ≥5%, severe dyspnoea or asthenia, chest pain, palpitations, anosmia/ageusia, headache, cutaneous signs, arthralgia, myalgia, digestive disorders, fever or sick leave. Results At D30, 68% (103/150) of patients had at least one symptom; and at D60, 66% (86/130) had symptoms, mainly anosmia/ageusia: 59% (89/150) at symptom onset, 28% (40/150) at D30 and 23% (29/130) at D60. Dyspnoea concerned 36.7% (55/150) patients at D30 and 30% (39/130) at D60. Half of the patients (74/150) at D30 and 40% (52/130) at D60 reported asthenia. Persistent symptoms at D60 were significantly associated with age 40 to 60 years old, hospital admission and abnormal auscultation at symptom onset. At D30, severe COVID-19 and/or dyspnoea at symptom onset were additional factors associated with persistent symptoms. Conclusions Up to 2 months after symptom onset, two thirds of adults with noncritical COVID-19 had complaints, mainly anosmia/ageusia, dyspnoea or asthenia. A prolonged medical follow-up of patients with COVID-19 seems essential, whatever the initial clinical presentation.

Subfields: Dermatology, Neurology, Sensory Systems

View Paper: https://www.semanticscholar.org/paper/d5a77da855f2424362e26782b46f589d584688f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

K. Nirantharakumar
Samantha Cruz Rivera
G. Price
S. Hughes
P. Schommers
Vanessa Priesner
C. Horn
Nikolai Tschernoster

Citations in the corpus

Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study (2021, background): “In recent research, time span to define the syndrome varied between >28 30 days [12,17], 60 days [12,16,17] or longer than 3 months [12,18].”
Symptoms, complications and management of long COVID: a review (2021, background): “However, there is evidence that the impact of acute COVID-19 on patients, regardless of severity, extends beyond hospitalisation in severe cases, to ongoing impaired quality of life, mental health and employment issues.(14,15,17,24) People living with long COVID have indicated that they are sufferin”
More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis (2021, neutral): “5 (19-84) 63 Fatigue, dyspnea, joint pain, chest pain, cough, anosmia, Sicca syndrome, Rhinitis, red eyes, dysgeusia, headache, sputum, lack of appetite, sore throat, vertigo, myalgia, diarrhea.”